Double "d" drug danger

AIDS Reader

Volumn 13, Issue 1, 2003, Pages 15-24

  Moyle, Graeme ^a  

^a NONE

Author keywords

Dideoxynucleosides; HIV AIDS; Hyperlactatemia; Lactic acidosis; Peripheral neuropathy; Wasting

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LEUKOCYTE COUNT; LIPODYSTROPHY; MAJOR CLINICAL STUDY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT DISORDER; TREATMENT OUTCOME; VIRUS INFECTION; WASTING SYNDROME;

EID: 0037247826     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Katlama C, Pellegrin JL, Lacoste D, et al. MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine. HIV Med. 2001;2:20-26.
2. Robbins G, Shafer R, Smeaton L, et al. Antiretroviral strategies in naive HIV+ subjects: comparisons of sequential 3-drug regimens (ACTG 384). In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract LbOr20A.
3. Saag M, Cahn P, Raffi F, et al. A randomized, double-blind, multicenter comparison of emtricitabine QD to stavudine BID. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract LB1.
4. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:153-161.
5. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf. 1998;19:481-494.
6. Marcus K, Truffa M, Boxwell D, Toerner J. Recently identified adverse events secondary to NRTI therapy in HIV-infected individuals: cases from the FDA's Adverse Event Reporting System (AERS). In: Program and abstracts of the 9th Annual Retrovirus Conference; February 24-28, 2002; Seattle. Abstract LB14.
7. Squires KE, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudme in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS. 2000;14:1591-1600.
8. Eron JJ Jr, Murphy RL, Peterson D, et al. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS. 2000;14:1601-1610.
9. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 2001;15:717-723.
10. Gerard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS. 2000;14:2723-2730.
11. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. 2001;33:1931-1937.
12. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-1349.
13. Dube M, Zackin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral naive subjects randomised to receive zidovudine + lamivudine or didanosine + stavudine combined with nelfinavir, efavirenz or both: A5005s, a substudy of ACTG 384. Antivir Ther. 2002;7(3 suppl 1):L18.
14. Baril JG, Pollard RB, Raffi F, et al. Stavudine extended release/prolonged release (XR/PRC) vs stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48-week efficacy and safety. In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract LbPeB9014.